FoundationOne® CDx - P170019/S017 | FDA
https://www.fda.gov/medical-devices/recently-approved-devices/foundationoner-cdx-p170019s017
What Is It?How Does It Work?When Is It used?What Will It Accomplish?Additional Information (Including Warnings, Precautions, and Adverse Events) F1CDx is used to help doctors decide if a patient with metastatic, solid tumors might be a candidate for treatment with VITRAKVI® (larotrectinib). This may be an option when the cancer has spread and the tumor removal is too risky, the tumors continue to grow after other treatments have been tried, or if there are no other treatments available.
F1CDx is used to help doctors decide if a patient with metastatic, solid tumors might be a candidate for treatment with VITRAKVI® (larotrectinib). This may be an option when the cancer has spread and the tumor removal is too risky, the tumors continue to grow after other treatments have been tried, or if there are no other treatments available.
DA: 90 PA: 92 MOZ Rank: 85
